Lineage Cell Therapeutics Inc (LCTX) Stock: What Does the Chart Say Monday?

The market has been high on Lineage Cell Therapeutics Inc (LCTX) stock recently. LCTX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Lineage Cell Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LCTX!

See Full LCTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LCTX Stock Today?

Lineage Cell Therapeutics Inc (LCTX) stock is trading at $1.48 as of 9:45 AM on Monday, Dec 5, a drop of -$0.02, or -1.33% from the previous closing price of $1.50. The stock has traded between $1.47 and $1.50 so far today. Volume today is less active than usual. So far 9,258 shares have traded compared to average volume of 370,188 shares.

More About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. Click Here to get the full Stock Report for Lineage Cell Therapeutics Inc stock.